Tumor Mutational Burden in Small Cell Lung Cancer: A Valuable Biomarker for Immunotherapy? (BMIC-011)
Oct 20, 2017•9 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Dr. Jack West reviews new findings highlighting the utility of using the biomarker tumor mutation burden (TMB) to predict which patients with small cell lung cancer (SCLC) will benefit from nivolumab or the combination of nivolumab with ipilimumab.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast